Shimizu Akihiko, Mitsuhashi Takeshi, Nitta Takashi, Mitamura Hideo, Kurita Takashi, Abe Haruhiko, Nakazato Yuji, Sumitomo Naokata, Kadota Kazushige, Kimura Kazuo, Okumura Ken
Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
Jichi Medical University Saitama Medical Center, Saitama, Japan.
J Arrhythm. 2015 Apr;31(2):83-7. doi: 10.1016/j.joa.2014.07.005. Epub 2014 Sep 12.
There is little information regarding appropriate therapies for coronary artery disease (CAD) patients with implantable devices - such as implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy devices (CRT-Ds) and cardiac resynchronization therapy pacemaker (CRT-P) devices - in Japan. To address this lack of information, we have launched the Japan Implantable Devices in Coronary Artery Disease (JID-CAD) study.
This study has been designed as a prospective, multicenter, non-randomized and observational investigation. All patients will be followed up every six months over a two-year period. The primary endpoint will be the administration of appropriate device therapy. Secondary endpoints include administration of inappropriate therapy, death, hospitalization, or cardiovascular events.
In this report, we discuss the current clinical situation of appropriate therapy, and how it is influenced by catheter ablation and revascularization therapy in patients with CAD.
在日本，关于患有植入式设备（如植入式心脏复律除颤器（ICD）、心脏再同步治疗设备（CRT-D）和心脏再同步治疗起搏器（CRT-P））的冠状动脉疾病（CAD）患者的适当治疗方法，相关信息较少。为了解决这一信息匮乏的问题，我们开展了日本冠状动脉疾病植入式设备（JID-CAD）研究。
本研究设计为一项前瞻性、多中心、非随机观察性调查。所有患者将在两年期间每六个月进行一次随访。主要终点将是适当的设备治疗的实施。次要终点包括不适当治疗的实施、死亡、住院或心血管事件。
在本报告中，我们讨论了适当治疗的当前临床情况，以及CAD患者中导管消融和血运重建治疗对其的影响。
